Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigatuzumab + Sorafenib in Advanced HCC
NCT01033240Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2010
- Primary completion
- Jul 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of tigatuzumab in hepatocellular carcinoma (HCC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2010; status: completed.
02
Drugs
tigatuzumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01033240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01033240.